Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura
Sign Up to like & getrecommendations! Published in 2019 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s134470
Abstract: Thrombotic thrombocytopenic purpura (TTP) is a rare disease with a mortality rate of over 90% if left untreated. Therapeutic plasma exchange (PEX) is the mainstay of treatment of acquired TTP (aTTP), and with the introduction… read more here.
Keywords: thrombocytopenic purpura; thrombotic thrombocytopenic; treatment; caplacizumab emerging ... See more keywords